fda glp-1 compounding warning letters september 2025 30 telehealth companies received U.S. Food and Drug Administration for falsely marketing products online. said these companies claimed that their compounded products are similar to generic FDA-approved products How GLP-1s Broke Healthcare Distribution
Description
This is not a GLP-1 receptor agonist

Suggested Use
The agency will continue to work with state regulators, monitor the market, and take enforcement actions as necessary to prevent unsafe or fraudulent GLP-1 drugs from reaching U.S

Meet GSLIM, a semaglutide alternative that is powerful, effective and safe.

Discover how pairing GLP-1 weight loss with aesthetic treatments like fillers & skin tightening creates a harmonious, natural beauty transformation
